Clinical Trial Update: Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke

View source ↗

Summary

An observational study comparing the safety of rhTNK-tPA (Mingfule) versus rt-PA (Actilyse) for acute ischemic stroke, with the registry showing not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Actilyse (alteplase)
• Mingfule (tenecteplase) (tenecteplase)

Snippet

Sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | Conditions: Acute Ischemic Stroke, rhTNK-tPA | Status: NOT_YET_RECRUITING